

June 11, 2026

The Manager- Listing

**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai - 400001

The Manager- Listing

**National Stock Exchange of India Limited**

Exchange plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra –Kurla Complex, Bandra (E),  
Mumbai - 400051

Dear Sir,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015**

This is to inform that on June 10, 2026, AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization, Directorate General of Health Services, Government of India to import for sale and distribution of Trastuzumab deruxtecan 100 mg/5mL vial lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu<sup>®</sup>) for an additional indication.

Through this approval, Trastuzumab deruxtecan in combination with pertuzumab is indicated for the first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+ or ISH+) breast cancer.

The receipt of this permission paves way for the marketing of Trastuzumab deruxtecan 100 mg/5mL vial lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu<sup>®</sup>) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.

We request you to take the above intimation on record.

Thanking you,

For **AstraZeneca Pharma India Limited**

**Tanya Sanish**

**Company Secretary & Compliance Officer**